Gelonghui May 6 丨 Xianju Pharmaceutical (002332)(002332popslotsfree.SZ) announcedpopslotsfreeRecently, Zhejiang Xianju Pharmaceutical Co., Ltd. received a notice from the U.S. Food and Drug Administration (referred to as "U.S. FDA") that the company's abbreviated new drug application (ANDA, or U.S. generic drug application) for prednisolone tablets submitted to the U.S. FDA has been approved.

Prednisolone tablets are glucocorticoids. Superphysiological amounts of glucocorticoids have multiple pharmacological effects such as anti-inflammation, anti-allergic and immunosuppression. It is mainly used for allergic and autoimmune inflammatory diseases and collagen diseases.